Go online to PeerView.com/SDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to develop personalized treatment plans for your patients with myelofibrosis (MF) that incorporate the latest therapeutic options, including JAK inhibitors, targeted strategies, and HCT? Find out in this new PeerView CME activity, featuring two experts who will use case-based clinical discussions to illustrate how they manage MF with the individual patient in mind. They will use these cases to discuss eligibility for HCT and the need for pre-HCT ..read more

Go online to PeerView.com/FNM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Find out if you are updated on the latest evidence and management considerations on the use of BCMA antibodies and CAR-T cell therapy for the management of multiple myeloma (MM) in this new PeerView learning CME video recorded at the 2023 Tandem Meetings. Watch the MM experts clarify the most recent practice-changing evidence with BCMA-directed treatments and hear them provide insight on rapidly emerging future applications. Throughout, the experts deliver take-h ..read more

Go online to PeerView.com/AEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to achieve therapeutic synergy in CLL and leverage the potency of targeted platforms along with emerging cellular therapy options? Find out by watching this “Clinical Consults” event recorded at the 2023 Tandem Meetings, where experts presenting the latest practice-changing evidence provide practical take-homes on the upfront and sequential use of covalent and noncovalent BTK and BCL-2 inhibitors, the emergence of potent chemo-sparing combinatori ..read more

Go online to PeerView.com/DFQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel antibody platforms—including agents directed against targets such as CD38 and BCMA—have proven efficacy in a range of multiple myeloma (MM) treatment settings and have clear treatment roles across the spectrum of care, from newly diagnosed MM to relapsed/refractory disease. Additionally, a new wave of immune-based treatments in the form of bispecific T-cell–engaging antibodies shows a great deal of promise and may soon add another layer of complexity to the ..read more

Go online to PeerView.com/KZP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Learn how to apply the evidence that supports modern therapeutics in conjunction with allogeneic hematopoietic stem cell (HCT)! This "Clinical Consults" activity features an expert-led, case-centered discussion focusing on therapeutic decision-making in HCT-eligible acute myeloid leukemia (AML). Throughout, the panelists weigh in on topics such as how to incorporate targeted options into the management of HCT-eligible patients based on FLT3 or TP53 mutations, sel ..read more

Go online to PeerView.com/FSN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. After many years of slow progress, the treatment arsenal has finally expanded and more hope is on the horizon for patients with small cell lung cancer (SCLC). Notable advances such as chemo-immunotherapy in the first-line setting and lurbinectedin in the second-line setting have now become guideline-recommended standards of care and propelled the treatment of SCLC forward. Further research efforts are focused on understanding the underlying biology and potential ..read more

Go online to PeerView.com/RYC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of precision oncology, extensive and nuanced biomarker testing of complex tumors such as non–small cell lung cancer (NSCLC) is essential to determine the best treatment approach for each patient. Targeted therapies are associated with improved outcomes, and the list of relevant therapeutic targets and matched therapies continues to expand, necessitating more granularity and precision in testing. Which tests are appropriate and how should their r ..read more

Go online to PeerView.com/NEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Although chimeric antigen receptor (CAR-T) cell therapy is primarily administered in the inpatient setting, delivery in the outpatient setting likely represents a more convenient and patient-friendly approach that could expand potentially life-saving treatment access for many patients with hematologic cancers. This “Learning Workshop” activity provides learners with the “tools of the trade” for building an outpatient infrastructure that is capable of expanding pa ..read more

Go online to PeerView.com/FTC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the cancer immunotherapy arsenal and its impact on patient care continues to expand, it’s more important than ever to refine testing for predictive biomarkers to guide patient selection and clinical decisions about treatment. Assessments of PD-L1 expression and MSI/MMR or TMB status have a role in some tumor types and treatment settings, but a number of challenges related to testing and interpretation of results remain, and better predictive tools are needed ..read more

Go online to PeerView.com/TBV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. BTK inhibitors have transformed the medical management of chronic lymphocytic leukemia (CLL) and led to similar advances for patients with mantle cell lymphoma (MCL) and other B-cell malignancies. These therapeutics have dramatically improved outcomes for patients but have also introduced challenges regarding optimal AE management because BTK inhibitors have unique safety profiles that differ from increasingly outdated immunochemotherapy regimens. In this activit ..read more